Journal
MOLECULAR CANCER RESEARCH
Volume 4, Issue 4, Pages 221-233Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-05-0261
Keywords
-
Categories
Funding
- NCI NIH HHS [CA094964, CA112557, CA103180] Funding Source: Medline
- NIEHS NIH HHS [ES012451] Funding Source: Medline
Ask authors/readers for more resources
Several recent studies have identified nuclear factor-kappa B as a key modulator in driving inflammation to cancers. Besides this transcription factor, essential in regulating inflammation and cancer development, an inflammatory microenvironment inhabiting various inflammatory cells and a network of signaling molecules are also indispensable for the malignant progression of transformed cells, which is attributed to the mutagenic predisposition of persistent infection-fighting agents at sites of chronic inflammation. As a subverted host response to inflammation-induced tumors, the inflammatory cells and regulators may facilitate angiogenesis and promote the growth, invasion, and metastasis of tumor cells. Thus far, research regarding inflammation-associated cancer development has focused on cytokines and chemokines as well as their downstream targets in linking inflammation and cancer. Moreover, other proteins with extensive roles in inflammation and cancer, such as signal transducers and activators of transcription, Nrf2, and nuclear factor of activated T cells, are also proposed to be promising targets for future studies. The elucidation of their specific effects and interactions will accelerate the development of novel therapeutic interventions against cancer development triggered by inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available